A Clinical Study to Evaluate the Effect of HDP-101 for the Treatment of Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 11 Oct 2018
At a glance
- Drugs HDP 101 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 11 Oct 2018 According to a Heidelberg Pharma AG media release, preparations for initiation of this trial are underway and several highly renowned centers have been enlisted for this trial with Heidelberg Pharma acting as a trial design advisor.
- 11 Oct 2018 According to a Heidelberg Pharma AG media release, the company has brought several important and renowned clinical centers in Germany, Spain and the USA on board for HDP-101 project and will continue to push ahead with trial planning together with these institutions.The company is planning to submit the trial application in the second quarter of 2019 and depending on how the approval procedure unfolds, the first patients could start receiving treatment in the second half of 2019.
- 19 Oct 2017 According to a Heidelberg Pharma AG media release, WILEX AG changed its name to Heidelberg Pharma AG.